A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients with ocular Graft-vs-Host Disease (oGVHD)

Administered By

Awarded By

Contributors

Start/End

  • January 11, 2019 - December 31, 2020